Nathaniel (Tanny) Bachrach, PhD, is Chief Executive Officer of PrintBio. Previously, he was the Chief Scientific Officer and Executive Vice President of 3DBio Therapeutics. Prior to 3DBio, he was the Vice President of Research & Technology at LifeCell (NASDAQ: LIFC), which was acquired by Allergan. He came to LifeCell from Organogenesis. Dr. Bachrach received his PhD, as well as B.S. and M.S. degrees, in Mechanical Engineering from Columbia University in New York, where his research focused on cartilage and regenerative medicine.

Stephen Pinto is EVP, Marketing & Commercial Strategy at PrintBio. He brings a strong background in commercial strategy with a focus on med-tech and surgical innovation. He has extensive experience developing go-to-market strategies, shaping value propositions, and supporting adoption of technologies that advance patient care. His work has emphasized bridging clinical needs with market dynamics to accelerate the success of new medical technologies.

Before joining PrintBio, Stephen held commercial strategy and marketing leadership roles at Pfizer, AbbVie and Bristol-Myers Squibb where he gained deep expertise in launching and scaling healthcare solutions in complex markets. At PrintBio, he is responsible for guiding the commercial pathway for the company’s programmable surgical mesh, ensuring it is positioned for meaningful adoption among surgeons, hospitals, and health systems.

Sue Woodring is Director, Sales Infrastructure and Enablement. She brings more than two decades of experience in commercial operations, market enablement and events within the medical device industry. She has led commercial infrastructure initiatives, global conventions and sales meetings for many including Sientra and LifeCell, where she supported product launches, branding strategies, and sales force execution across multiple markets.

At PrintBio, Sue is responsible for building the selling infrastructure that will enable the company’s entry into market. Her role spans the full commercial backbone — from ordering systems and customer service to sales operations and enablement — ensuring that PrintBio’s programmable surgical mesh can be seamlessly adopted by surgeons and health systems.

Kayvon Namvar is Founder and Manager of Lookout Ridge Capital Advisors. Previously, he was a Principal at RNA Advisors, a team of financial advisors, strategy consultants, and valuation experts dedicated to companies and investors. He has deep expertise in forecasting, valuation, litigation support, and transaction advisory support.

In life sciences, Kayvon has developed dynamic patient-flow and other financial models to facilitate the forecasting and valuation of biopharmaceutical, medical device and diagnostic products, companies, complex securities, and royalty interests for transaction, bankruptcy, tax, and accounting oriented purposes. Kayvon holds a Bachelor of Science degree in Business Administration with a concentration in Corporate Finance from the University of Southern California.

Jill Tierney is the Controller at PrintBio. Ms. Tierney specializes in standing up early-stage biotech organizations. She currently advises multiple venture capitalist backed portfolio companies and reports directly to the CEO and Board of Directors as well as serves as the Vice President of Finance at AsclepiX Therapeutics, Inc. Prior to these current roles, she served as the Manager of FP&A at Aerie Pharmaceutics and was involved in the expansion of the company’s finance department during its transition from development-stage to a fully integrated commercial organization. Ms. Tierney has over 15 years of experience in corporate finance, financial planning and analysis in the pharmaceutical and healthcare industries.

Kevin Slawin, M.D. is the Founder and Managing Partner of Rapha Capital Management, LLC (https://raphacap.com). Formerly a robotic oncologic surgeon, he is now a biotech investor and founder focusing on disruptive healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc., leading Bellicum to a successful $161 million IPO in December, 2014. He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as the board Chairman of FIZE Medical, Inc. (https://fizemedical.com). He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. (https://asclepix.com) in 2020, engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. Rapha Capital Management offers alternative asset management services to its private equity fund, Rapha Capital PE Life Sciences Fund VI (https://raphacapitalpe.com) which is the current vehicle for all investments managed by Rapha Capital Management.

He is also the founder and CEO of Ponce Therapeutics, Inc. (https://poncetherapeutics.com), which reunites the team that founded Bellicum Pharmaceuticals and that is using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging, and DELiver Therapeutics, Inc. (https://delivertherapeutics.com), which is applying high throughput DNA encoded library (DEL) drug screening combined with other advanced technologies in novel ways to deliver small molecule and peptide therapeutics that address some of the most challenging and, some previously termed “undruggable”, targets in clinical medicine.  Both have R&D facilities located at K2Bio in Houston (https://www.k2-biolabs.com/), a coworking research facility for biotech and pharma startups recently opened in Houston, where he is a co-founder, investor, and board member.  He is also the Founder and Chairman of PrintBio, Inc. (https://printbio.com), a commercial-stage medical device company and creator of the first programmable surgical mesh platform.

Slawin graduated magna cum laude with a Bachelor of Arts degree in Biochemistry from Columbia University, where he was inducted into Phi Beta Kappa. He earned his medical degree in 1986 from Columbia College of Physicians and Surgeons and was elected to the Alpha Omega Alpha honor society. He trained in General Surgery and then Urology at the Mount Sinai Hospital and at Squier Urologic Clinic at Columbia Presbyterian Hospital, both in NYC. Later, he was awarded a two-year fellowship, from 1992-1994, as an American Foundation of Urologic Disease (AFUD) scholar at Baylor College of Medicine to continue to study the development and treatment of prostate cancer under the tutelage of renowned prostate cancer surgeon and thought leader, Dr. Peter Scardino. Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994 and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, established by the well-known Houston oil man and philanthropist of the same name. He is co-Inventor of the FDA-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America’s Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.  He currently lives in Miami, FL where he is Founder and CEO of Miami Medicos (https://miamimedicos.com), a membership organization of physicians, founders, executives, and investors catalyzing the healthcare entrepreneurial ecosystem in Miami and worldwide.

Brent Saunders was previously CEO of Allergan, the company that developed and launched Botox™ until its acquisition by AbbVie Inc. in 2020.